Skip to main content

Advertisement

SpringerLink
Log in

FGFR3-related dwarfism and cell signaling

  • Review Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Superti-Furga A, Bonafe L, Rimoin DL (2001) Molecular-pathogenetic classification of genetic disorders of the skeleton. Am J Med Genet 106(4):282–293

    Article  PubMed  CAS  Google Scholar 

  2. Hall CM (2002) International nosology and classification of constitutional disorder of bone (2001). Am J Med Genet 113(1):65–77

    Article  PubMed  Google Scholar 

  3. Kornak U, Mundlos S (2003) Genetic disorders of the skeleton: a developmental approach. Am J Hum Genet 73(3):447–474

    Article  PubMed  CAS  Google Scholar 

  4. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335–342

    Article  PubMed  CAS  Google Scholar 

  5. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Marotearx P, Le MM, Munnich A (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature (Lond) 371:252–254

    Article  CAS  Google Scholar 

  6. Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA (1995) A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 10(3):357–359

    Article  PubMed  CAS  Google Scholar 

  7. Bellus GA, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA (2000) Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 67:1411–1421

    Article  PubMed  CAS  Google Scholar 

  8. Tavormina PL, Ahiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ (1995) Thanatophoric dysplasia (type I and type II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321–328

    Article  PubMed  CAS  Google Scholar 

  9. Tavormina PL, Rimon DL, Cohn DH, Zhu YZ, Shiang R, Wamuth JJ (1995) Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet 4:2175–2177

    Article  PubMed  CAS  Google Scholar 

  10. Rousseau F, Saugier P, LeMerrer M, Munnich A, Delezoide AL, Moroteaux P, Bonaventure J, Narcy F, Sanak M (1995) Stop codon FGFR3 mutation in thanatophoric dwarfism type I. Nat Genet 10:11–12

    Article  PubMed  CAS  Google Scholar 

  11. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, Mclntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA (1999) A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 64:722–731

    Article  PubMed  CAS  Google Scholar 

  12. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911–921

    Article  PubMed  CAS  Google Scholar 

  13. Weksler NB, Lunstrum GP, Reid ES, Horton WA (1999) Differential effects of fibroblast growth factor (FGF) 9 and FGF2 on proliferation, differentiation and terminal differentiation of chondrocytic cells in vitro. Biochem J 342(pt 3):677–682

    Article  PubMed  CAS  Google Scholar 

  14. De Luca F, Baron J (1999) Control of bone growth by fibroblast growth factors. Trends Endocrinol Metab 10(2):61–65

    Article  PubMed  Google Scholar 

  15. Legeai-Mallet L, Benoist-Lasselin C, Munnich A, Bonaventure J (2004) Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone (NY) 34(1):26–36

    CAS  Google Scholar 

  16. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12(4):390–397

    Article  PubMed  CAS  Google Scholar 

  17. Pantoliano MW, Horlick RA, Springer BA, Van Dyk DE, Tobery T, Wetmore DR, Lear JD, Nahapetian AT, Bradley JD, Sisk WP (1994) Multivalent ligand–receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 33(34):10229–10248

    Article  PubMed  CAS  Google Scholar 

  18. Shi E, Kan M, Xu J, Wang F, Hou J, McKeehan WL (1993) Control of fibroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants. Mol Cell Biol 13(7):3907–3918

    PubMed  CAS  Google Scholar 

  19. Peters K, Ornitz D, Werner S, Williams L (1993) Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev Biol 155(2):423–430

    Article  PubMed  CAS  Google Scholar 

  20. Hughes SE (1997) Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 45(7):1005–1019

    PubMed  CAS  Google Scholar 

  21. Vajo Z, Francomano CA, Wilkin DJ (2000) The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 21(1):23–39

    Article  PubMed  CAS  Google Scholar 

  22. Kannan K, Givol D (2000) FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models. IUBMB Life 49(3):197–205

    PubMed  CAS  Google Scholar 

  23. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A (1996) Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Horm Res 45(1–2):108–110

    Google Scholar 

  24. Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA (1995) A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 10(3):357–359

    Article  PubMed  CAS  Google Scholar 

  25. Grigelioniene G, Hagenas L, Eklof O, Neumeyer L, Haereid PE, Anvret M (1998) A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online. Hum Mutat 11(4):333

    Article  PubMed  CAS  Google Scholar 

  26. Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA (2000) Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 67(6):1411–1421

    Article  PubMed  CAS  Google Scholar 

  27. Winterpacht A, Hilbert K, Stelzer C, Schweikardt T, Decker H, Segerer H, Spranger J, Zabel B (2000) A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol Genomics 2(1):9–12

    PubMed  CAS  Google Scholar 

  28. Brodie SG, Kitoh H, Lachman RS, Nolasco LM, Mekikian PB, Wilcox WR (1999) Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. Am J Med Genet 84(5):476–480

    Article  PubMed  CAS  Google Scholar 

  29. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ (1995) Thanatophoric dysplasia (type I and type II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321–328

    Article  PubMed  CAS  Google Scholar 

  30. Tavormina PL, Rimoin DL, Cohn DH, Zhu YZ, Shiang R, Wasmuth JJ (1995) Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet 4:2175–2177

    Article  PubMed  CAS  Google Scholar 

  31. Rousseau F, Saugier P, Le Merrer M, Munnich A, Delezoide AL, Maroteaux P, Bonaventure J, Narcy F, Sanak M (1995) Stop codon FGFR3 mutation in thanatophoric dwarfism type I. Nat Genet 10:11–12

    Article  PubMed  CAS  Google Scholar 

  32. Webster MK, D’Avis PY, Robertson SC, Donoghue DJ (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16(8):4081–4087

    PubMed  CAS  Google Scholar 

  33. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA (1999) Novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 64:722–731

    Article  PubMed  CAS  Google Scholar 

  34. Bellus GA, Bamshad MJ, Przylepa KA, Dorst J, Lee RR, Hurko O, Jabs EW, Curry CJ, Wilcox WR, Lachman RS, Rimoin DL, Francomano CA (1999) Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet 85(1):53–65

    Article  PubMed  CAS  Google Scholar 

  35. McAlister WH, Crane JP, Bucy RP, Craig RB (1985) A new neonatal short limbed dwarfism. Skeletal Radiol 13(4):271–275

    Article  PubMed  CAS  Google Scholar 

  36. Langer LO Jr, Baumann PA, Gorlin RJ (1967) Achondroplasia. Am J Roentgenol 100:12–26

    Google Scholar 

  37. Hecht JT, Thompson NM, Weir T, Patchell L, Horton WA (1991) Cognitive and motor skills in achondroplastic infants: neurologic and respiratory correlates. Am J Hum Genet 41:208–211

    CAS  Google Scholar 

  38. Cohen MM Jr, Walker GF, Phillips C (1985) Morphometric analysis of the craniofacial configuration in achondroplasia. J Craniofac Genet Dev Biol 1:139–165

    Google Scholar 

  39. Rousseau F, Bonaventure J, Logeai-Mallet L, Schmidt H, Wessenbach J, Maroteaux P, Munnich A, Le Merrer M (1996) Clinical and genetical heterogeneity of hypochondroplasia. J Med Genet 33:749–752

    Article  PubMed  CAS  Google Scholar 

  40. Ramaswami U, Rumsby G, Hindmarsh PC, Brook CGD (1998) Genotype and phenotype in hypochondroplasia. J Pediatr 133:99–102

    Article  PubMed  CAS  Google Scholar 

  41. Connor JM, Connor RAC, Sweet EM, Gibson AAM, Patrick WJA, McNay MB, Redford DHA (1985) Lethal neonatal chondrodysplasias in the West of Scotland, 1970–1983, with a description of a thanatophoric, dysplasia like, autosomal recessive disorder, Glasgow variant. Am J Med Genet 22:243–253

    Article  PubMed  CAS  Google Scholar 

  42. Martinez-Frias ML, Ramos-Arroyo MA, Salvador J (1988) Thanatophoric dysplasia: an autosomal dominant condition? Am J Med Genet 31:815–820

    Article  PubMed  CAS  Google Scholar 

  43. Elejalde BR, de Elejalde MM (1985) Thanatophoric dysplasia: fetal manifestations and prenatal diagnosis. Am J Med Genet 22(4):669–683

    Article  PubMed  CAS  Google Scholar 

  44. Langer LO Jr, Yang SS, Hall JG, Sommer A, Kottamasu SR, Golabi M, Krassikoff N (1987) Thanatophoric dysplasia and cloverleaf skull. Am J Med Genet Suppl 3:167–179

    Article  PubMed  Google Scholar 

  45. Norman AM, Rimmer S, Landy S, Donnai D (1992) Thanatophoric dysplasia of the straight-bone type (type 2). Clin Dysmorph 1:115–120

    PubMed  CAS  Google Scholar 

  46. Giedion A (1968) Thanatophoric dwarfism. Helv Paediat Acta 23:175–183

    PubMed  CAS  Google Scholar 

  47. Bellus GA, Bamshad MJ, Przylepa KA, Dorst J, Lee RR, Hurko L, Jabs EW, Curry CJ, Wilcox WR, Lachman RS, Rimoin DL, Francomano CA (1999) Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet 85(1):53–65

    Article  PubMed  CAS  Google Scholar 

  48. Naski MC, Wang Q, Xu J, Ornitz DM (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13:233–237

    Article  PubMed  CAS  Google Scholar 

  49. Lievens PM, Liboi E (2003) The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem 278(19):17344–17349

    Article  PubMed  CAS  Google Scholar 

  50. Lievens PMJ, Mutinelli C, Daynes D, Liboi E (2004) The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem 279(41):43254–43260

    Article  PubMed  CAS  Google Scholar 

  51. Harada D, Yamanaka Y, Ueda K, Nishimura R, Morishima T, Seino Y, Tanaka H (2007) Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLC-gamma-activated STAT1. Bone (NY) 41(2):273–281

    CAS  Google Scholar 

  52. Webster MK, Donoghue DJ (1996) Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15(3):520–527

    PubMed  CAS  Google Scholar 

  53. Ornitz DM, Marie PJ (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16(12):1446–1465

    Article  PubMed  CAS  Google Scholar 

  54. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16(2):139–149

    Article  PubMed  CAS  Google Scholar 

  55. L’Hote CG, Knowles MA (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 304(2):417–431

    Article  PubMed  CAS  Google Scholar 

  56. Horton WA, Hall JG, Hacht JT (2007) Achondroplasia. Lancet 370:162–172

    Article  PubMed  CAS  Google Scholar 

  57. Hart KC, Robertson SC, Donoghue DJ (2001) Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 22:931–942

    Google Scholar 

  58. Koike M, Yamanaka Y, Inoue M, Tanaka H, Nishimura R, Seino Y (2003) Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK. J Bone Miner Res 18:2043–2051

    Article  PubMed  CAS  Google Scholar 

  59. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, Tamura N, Ogawa Y, Nakao K (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10(1):80–86

    Article  PubMed  CAS  Google Scholar 

  60. Naski MC, Colvin JS, Coffin JD, Ornitz DM (1998) Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development (Camb) 125:4977–4988

    CAS  Google Scholar 

  61. Yamanaka Y, Tanaka H, Koike M, Nishimura R, Seino Y (2003) PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation. J Bone Miner Res 18:1395–1403

    Article  PubMed  CAS  Google Scholar 

  62. Tanaka H, Kubo T, Yamate T, Ono T, Kanzaki S, Seino Y (1998) Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. Eur J Endocrinol 138(3):275–280

    Article  PubMed  CAS  Google Scholar 

  63. Ramaswami U, Hindmarsh PC, Brook CG (1999) Growth hormone therapy in hypochondroplasia. Acta Paediatr Suppl 88(428):116–117

    Article  PubMed  CAS  Google Scholar 

  64. Yamanaka Y, Seino Y, Shinohara M, Ikegami S, Koike M, Miyazawa M, Inoue M, Moriwake T, Tanaka H (2000) Growth hormone therapy in achondroplasia. Horm Res 53(suppl 3):53–56

    PubMed  Google Scholar 

  65. Kanazawa H, Tanaka H, Inoue M, Yamanaka Y, Namba N, Seino Y (2003) Efficacy of growth hormone therapy for patients with skeletal dysplasia. J Bone Miner Metab 21(5):307–310

    Article  PubMed  CAS  Google Scholar 

  66. Yasui N, Kawabata H, Kojimoto H, Ohno H, Matsuda S, Araki N, Shimomura Y, Ochi T (1997) Lengthening of the lower limbs in patients with achondroplasia and hypochondroplasia. Clin Orthop Relat Res 344:298–306

    Article  PubMed  Google Scholar 

  67. Aldegheri R, Dall’Oca C (2001) Limb lengthening in short stature patients. J Pediatr Orthop B 10(3):238–247

    Article  PubMed  CAS  Google Scholar 

  68. Aviezer D, Golembo M, Yayon A (2003) Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia: genetic short limbed dwarfism. Curr Drug Targets 4(5):353–365

    Article  PubMed  CAS  Google Scholar 

  69. Ueda K, Yamanaka Y, Harada D, Yamagami E, Tanaka H, Seino Y (2007) PTH has the potential to rescue disturbed bone growth in achondroplasia. Bone (NY) 41(1):13–18

    CAS  Google Scholar 

  70. Hagiwara H, Sakaguchi H, Itakura M, Yoshimoto T, Furuya M, Tanaka S, Hirose S (1994) Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. J Biol Chem 269(14):10729–10733

    PubMed  CAS  Google Scholar 

  71. Bartels CF, Bukulmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih L-Y, Al-Gazali LI, Kant S, Cole T, Morton J, Cormier-Daire V, Faivre L, Lees M, Kirk J, Mortier GR, Leroy J, Zabel B, Kim CA, Crow Y, Braverman NE, van den Akker F, Warman ML (2004) Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 75:27–34

    Article  PubMed  CAS  Google Scholar 

  72. Potter LR, Abbey-Hosch S, Dickey DM (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27:47–72

    Article  PubMed  CAS  Google Scholar 

  73. Rauchenberger R, Borges E, Thomassen-Wolf E, Rom E, Adar R, Yaniv Y, Malka M, Chumakov I, Kotzer S, Resnitzky D, Knappik A, Reiffert S, Prassler J, Jury K, Waldherr D, Bauer S, Kretzschmar T, Yayon A, Rothe C (2003) Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem 38:38194–38205

    Article  Google Scholar 

  74. Aviezer D, Golembo M, Yayon A (2003) Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia: genetic short limbed dwarfism. Curr Drug Targets 4(5):353–365

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Okayama University Graduated School of Medicine and Dentistry, 2-5-1, Shikata-cho, Okayama, 700-8558, Japan

    Daisuke Harada & Yoshitaka Yamanaka

  2. Department of Pediatrics, Matsuyama Red Cross Hospital, Ehime, Japan

    Koso Ueda

  3. Department of Pediatrics, Okayama Saiseikai General Hospital, Okayama, Japan

    Hiroyuki Tanaka

  4. Department of Pediatrics, Osaka Kosei-nenkin Hospital, Osaka, Japan

    Yoshiki Seino

Authors
  1. Daisuke Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitaka Yamanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koso Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyuki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiki Seino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daisuke Harada.

Additional information

D. Harada is a recepient of JSBMR Encouragement Award of 2004.

About this article

Cite this article

Harada, D., Yamanaka, Y., Ueda, K. et al. FGFR3-related dwarfism and cell signaling. J Bone Miner Metab 27, 9–15 (2009). https://doi.org/10.1007/s00774-008-0009-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-008-0009-7

Keywords

Search

Navigation